These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Elevated melatonin levels in natalizumab-treated female patients with relapsing-remitting multiple sclerosis: relationship to oxidative stress. Bahamonde C; Conde C; Agüera E; Lillo R; Luque E; Gascón F; Feijóo M; Cruz AH; Sánchez-López F; Túnez I Eur J Pharmacol; 2014 May; 730():26-30. PubMed ID: 24582759 [TBL] [Abstract][Full Text] [Related]
3. [Natalizumab and reduction of carbonylated proteins in patients with multiple sclerosis]. Tasset I; Aguera E; Gascon F; Giraldo AI; Salcedo M; Cruz AH; Sanchez F; Tunez I Rev Neurol; 2012 Apr; 54(8):449-52. PubMed ID: 22492096 [TBL] [Abstract][Full Text] [Related]
4. Natalizumab is Effective for the Treatment of Relapsing-remitting Tumefactive Multiple Sclerosis. Nakamura M; Itani K; Miyake K; Kunieda T; Kaneko S; Kusaka H Intern Med; 2017; 56(2):211-214. PubMed ID: 28090055 [TBL] [Abstract][Full Text] [Related]
5. Is natalizumab a breakthrough in the treatment of multiple sclerosis? Doggrell SA Expert Opin Pharmacother; 2003 Jun; 4(6):999-1001. PubMed ID: 12783595 [TBL] [Abstract][Full Text] [Related]
6. Neurofilament light antibodies in serum reflect response to natalizumab treatment in multiple sclerosis. Amor S; van der Star BJ; Bosca I; Raffel J; Gnanapavan S; Watchorn J; Kuhle J; Giovannoni G; Baker D; Malaspina A; Puentes F Mult Scler; 2014 Sep; 20(10):1355-62. PubMed ID: 24515731 [TBL] [Abstract][Full Text] [Related]
10. Biomarkers identification for PML monitoring, during Natalizumab (Tysabri®) treatment in Relapsing-Remitting Multiple Sclerosis. Lanza Cariccio V; Bramanti P; Mazzon E Mult Scler Relat Disord; 2018 Feb; 20():93-99. PubMed ID: 29353737 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: a post-marketing observational study. Sangalli F; Moiola L; Bucello S; Annovazzi P; Rizzo A; Radaelli M; Vitello G; Grimaldi LM; Ghezzi A; Martinelli V; Comi G Neurol Sci; 2011 Jan; 31 Suppl 3():299-302. PubMed ID: 20544247 [TBL] [Abstract][Full Text] [Related]
12. [Natalizumab as induction therapy in multiple sclerosis]. Corlobé A; Charif M; Mania A; Outteryck O; de Sèze J; Labauge P Rev Neurol (Paris); 2014 Jan; 170(1):2-5. PubMed ID: 24125463 [TBL] [Abstract][Full Text] [Related]
13. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Havrdova E; Galetta S; Hutchinson M; Stefoski D; Bates D; Polman CH; O'Connor PW; Giovannoni G; Phillips JT; Lublin FD; Pace A; Kim R; Hyde R Lancet Neurol; 2009 Mar; 8(3):254-60. PubMed ID: 19201654 [TBL] [Abstract][Full Text] [Related]
14. [Natalizumab in the treatment of patients with relapsing-remitting multiple sclerosis: the preliminary results of the observational program "Sovet"]. Popova EV; Brylev LV; Davydovskaia MV Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(2 Pt 2):79-82. PubMed ID: 23528599 [TBL] [Abstract][Full Text] [Related]